CAS: 34493-98-6; Dibekacin

该化合物是一种主要用于治疗Gram-阴性细菌严重感染的抗生素的微粒体外抗生素,对抗其他抗生素的菌株特别有效;二bekacin的化学结构具有氨基糖的复杂安排,它有助于其行动机制,抑制细菌蛋白合成;这种抗生素一般由于口服生物利用率低而通过注射进行;Dibekacin展示了广泛的活动,在临床环境中,特别是对于免疫系统受损的病人来说,具有价值;然而,它与其他微粒体外的病人一样,具有...

结构式图片

MSDS等安全信息

    上下游产品

    CAS号63770-47-8 (2S,3R,4S,5S,6R... | CAS号108050-24-4 penta-N-acetyld... | CAS号84039-25-8 1,3,2',6',3''-p... | CAS号84039-24-7 1,3,2',6',3''-p... | CAS号79384-36-4 O-3-acetamido-2... | CAS号113922-91-1 diethyl ((1R,3S... | CAS号113886-46-7 (2R,3S,4S,5R,6R... | CAS号41624-06-0 4-dec-9-enylide... | CAS号113886-52-5 (4R,6S,7R,7aS)-... | CAS号113886-47-8

    合成工艺路线路线简述

      海关参考信息

      专利信息


      专利号:US-10925977-B2
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
      发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
      权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
      摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

      专利号:US-RE28647-E
      优先权日:1971-06-02
      标 题:Preparation of 3-4 dideoxykanamycin B active against resistant bacteria
      摘要:Synthesis of 3''-4''-dideoxykanamycin B which comprises protecting the amino and all or a part of the hydroxyl groups other than 3'' and 4''-hydroxyl groups of kanamycin B, sulfonylating 3''- and 4''hydroxyl groups to give a derivative having disulfonic ester groups, removing said ester groups to give 3''-4''-unsaturated compound, reducing said compound and finally removing the residual protecting groups.

      专利号:US-8147805-B2
      优先权日:2005-01-05
      标题:Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications
      发明人:YANG DAVID; YU DONGFANG; CHANDA MITHU; AZHDARINIA ALI; OH CHANGSOK; KIM E EDMUND
      权利人:YANG DAVID; YU DONGFANG; CHANDA MITHU; AZHDARINIA ALI; OH CHANGSOK; KIM E EDMUND; UNIV T EXAS SYSTEM BOARD OF REGENTS
      摘要:Compositions and methods for dual imaging and for dual chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns compounds comprising the structure X 1 —Y—X 2 , wherein Y comprises two or more carbohydrate residues covalently attached to one another, X 1 and X 2 are diagnostic or therapeutic moieties covalently attached to Y, provided that when Y does not comprise a glucosamine residue, X 1 and X 2 are diagnostic moieties. The present invention also concerns methods of synthesis of these compounds, application of such compounds for dual imaging and treatment of hyperproliferative disease, and kits for preparing a radiolabeled therapeutic or diagnostic compound.

      专利号:US-10472663-B2
      优先权日:2015-01-21
      标 题:Procedure for the rapid determination of bacterial susceptibility to antibiotics that inhibit protein synthesis
      发明人:FERNÃ?NDEZ GARCÃ?A JOSÉ LUIS; GOSÃ?LVEZ BERENGUER JAIME; BOU ARÉVALO GERMÃ?N; TAMAYO NOVAS MARIA; SANTISO BRANDARIZ REBECA; OTERO FARIÑA FÃ?TIMA MARÃ?A
      权利人:ABM TECH LLC
      摘要:The present invention relates to a method for the rapid evaluation of bacterial susceptibility or non-susceptibility of bacteria to antibiotics that inhibit protein synthesis. The rationale is to identify bacterial responses that depend or are influenced by protein synthesis. If this response is prevented or reduced by the antibiotic that inhibits the protein synthesis, the bacteria are susceptible to this antibiotic. Otherwise, if the response keeps similar despite the incubation with the antibiotic, the bacteria are not susceptible or resistant to this antibiotic. These responses could be determined at the DNA lev-el, cell wall level, morphological level or any other experimental approach, including metabolic, bio-chemical, physiological or genetic processes.

      专利号:US-10814013-B2
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

      专利号:AU-2007308022-A2
      优先权日:2006-10-05
      标题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
      成都新恒创药业有限公司
      ⚠️ 未注册 · 未认证企业
      ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
      数据来源于公开网络搜索,平台未作核实,请自行辨别。
      🏢敬请 企业认领
      🏬开设公司展台
      📢获取免费会员权益
      🎖️点亮专属注册企业标签
      📇展现公司完整信息 样本查看立即注册认领 →
      网址: http://www.sino-strong.com.cn
      电话: 028-82666753👤
      📞成都新恒创药业有限公司 ⚠️参考联系方式

      销售电话:028-82666753
      邮箱:sales@sino-strong.com.cn
      🆔 联系时候可告知是从"百琢研"平台获取的信息.
      ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

      ⚠️ 未注册 · 未认证企业
      注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
      第 1 / 1 页
      现货

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Umemura E, Sakamoto Y, Takahashi Y, Miyake T. Synthesis and antibacterial activity of 1-N-[(S)-ω-amino-2-hydroxyalkyl] derivatives of dibekacin, 5-deoxydibekacin, 3'-deoxykanamycin A and gentamicin B. J Antibiot (Tokyo). 2015 Jun;68(6):421-3. doi: 10.1038/ja.2015.6. Epub 2015 Feb 25. French. doi: 10.1038/ja.2015.61. Epub 2015 May 20. Review. doi: 10.1128/AAC.03354-14. Epub 2014 Aug 4.
      7: Takeshima Y. [Genetic Diagnosis and Molecular Therapies for Duchenne Muscular Dystrophy]. Rinsho Byori. 2015 Oct;63(10):1194-201. Review. Japanese. German. doi: 10.1016/j.jiac.2014.05.007. Epub 2014 Jun 25. doi: 10.3346/jkms.2015.30.6.688. Epub 2015 May 13.
      12: Komiya I, Murata S, Umemura K, Tomono N, Kikai S, Fujita M. Acute toxicity and pharmacokinetics of dibekacin mice. J Pharmacobiodyn. 1981 May;4(5):356-61. doi: 10.1016/j.jcjo.2015.05.006. Epub 2015 Jul 23. doi: 10.1128/AAC.04839-14. Epub 2015 Mar 23.

      合成参考文献


      参考文献:10.1007/bf01718247
      摘要:Lobert PE, Hober D, Delannoy AS, Wattré P. Evidence that neomycin inhibits human cytomegalovirus infection of fibroblasts. Arch Virol. 1996;141(8):1453–62. doi: 10.1007/bf01718247.
      摘要:Hamada Y, Tamura K, Koyama I, Seki M, Yago K, Sunakawa K, Kuroyama M. Evaluation of arbekacin anti-MRSA agents for adult in Japan. Jpn J Antibiot. 2012 Aug;65(4):221–34.
      摘要:Kimura M, Yamagishi Y, Kawasumi N, Mikamo H. [Clinical investigation of arbekacin sulfate based on Cmax/MIC]. Jpn J Antibiot. 2012 Aug;65(4):263–9.
      参考文献:10.1007/s10156-012-0519-z
      摘要:Matsumoto T, Hanaki H, Kimura T, Nemoto M, Higashihara M, Yokota H, Oda S, Akiyama N, Miyao N, Yoshida M, Yukioka T, Soma K, Ohyashiki K, Suzuki Y, Arai T, Ikegami K, Ichiwata T, Otsuka Y, Kobayashi M, Totsuka K, Sunakawa K; ABK Dose Finding Study Group. Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study. J Infect Chemother. 2013 Feb;19(1):128–37. doi: 10.1007/s10156-012-0519-z.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知